Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study
Abstract Introduction Despite the declining public health emergency status, COVID-19 still poses significant risks, especially for immunocompromised individuals. We aimed to evaluate the effectiveness of tixagevimab-cilgavimab (T-C) prophylaxis in preventing severe COVID-19 in patients with hematolo...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-12-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-024-01089-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571437650542592 |
|---|---|
| author | Hovav Azuly Tali Shafat Daniel Grupel Tzvika Porges Ran Abuhasira Ana Belkin Ofir Deri Yonatan Oster Shadi Zahran Ehud Horwitz Netanel A. Horowitz Hazim Khatib Marjorie Vieira Batista Anita Cassoli Cortez Tal Brosh-Nissimov Yafit Segman Linor Ishay Regev Cohen Alaa Atamna Amy Spallone Roy F. Chemaly Juan Carlos Ramos Michal Chowers Evgeny Rogozin Noga Carmi Oren Şiran Keske Orit Wolfovitz Barchad Lior Nesher on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV) |
| author_facet | Hovav Azuly Tali Shafat Daniel Grupel Tzvika Porges Ran Abuhasira Ana Belkin Ofir Deri Yonatan Oster Shadi Zahran Ehud Horwitz Netanel A. Horowitz Hazim Khatib Marjorie Vieira Batista Anita Cassoli Cortez Tal Brosh-Nissimov Yafit Segman Linor Ishay Regev Cohen Alaa Atamna Amy Spallone Roy F. Chemaly Juan Carlos Ramos Michal Chowers Evgeny Rogozin Noga Carmi Oren Şiran Keske Orit Wolfovitz Barchad Lior Nesher on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV) |
| author_sort | Hovav Azuly |
| collection | DOAJ |
| description | Abstract Introduction Despite the declining public health emergency status, COVID-19 still poses significant risks, especially for immunocompromised individuals. We aimed to evaluate the effectiveness of tixagevimab-cilgavimab (T-C) prophylaxis in preventing severe COVID-19 in patients with hematologic malignancies (HM) treated with anti-CD20 therapy during the early Omicron variant phase of the pandemic. Methods The European Society of Clinical Microbiology and Infectious Diseases Study Group for Respiratory Viruses (ESGREV) conducted a multicenter retrospective cohort study involving 15 centers from 5 countries. The study included 749 patients with HM treated with anti-CD20 between February 15 and June 30, 2022, comparing 215 who received T-C prophylaxis to 534 who did not. Results The study revealed a significant reduction in the risk of COVID-19 among patients who received T-C prophylaxis compared to those who did not (11.2% vs 23.4%, p < 0.001), with hazard ratio (HR) of 0.40 (95% CI 0.26–0.63), adjusted for age, sex, vaccination status, baseline HM malignancy and type of anti-CD-20. We also demonstrated a reduction for severe-critical diseases within all study populations, 1.4% vs 5.2%, p = 0.017, HR 0.26 (95% CI 0.08–0.84). Conclusion T-C prophylaxis effectively prevented COVID-19 and severe-critical COVID-19 in patients with HM treated with anti-CD20 monoclonal antibodies during the early Omicron variant phase of the pandemic. Even though T-C is ineffective against current variants, these findings highlight the importance of additional protective measures and the continued development of monoclonal antibodies to protect immunocompromised individuals to mitigate the impact of COVID-19 and other respiratory viral diseases. |
| format | Article |
| id | doaj-art-3ea96b2063cf4a9598e2f0ef768524d6 |
| institution | Kabale University |
| issn | 2193-8229 2193-6382 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Infectious Diseases and Therapy |
| spelling | doaj-art-3ea96b2063cf4a9598e2f0ef768524d62025-02-02T12:35:22ZengAdis, Springer HealthcareInfectious Diseases and Therapy2193-82292193-63822024-12-0114116718010.1007/s40121-024-01089-9Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter StudyHovav Azuly0Tali Shafat1Daniel Grupel2Tzvika Porges3Ran Abuhasira4Ana Belkin5Ofir Deri6Yonatan Oster7Shadi Zahran8Ehud Horwitz9Netanel A. Horowitz10Hazim Khatib11Marjorie Vieira Batista12Anita Cassoli Cortez13Tal Brosh-Nissimov14Yafit Segman15Linor Ishay16Regev Cohen17Alaa Atamna18Amy Spallone19Roy F. Chemaly20Juan Carlos Ramos21Michal Chowers22Evgeny Rogozin23Noga Carmi Oren24Şiran Keske25Orit Wolfovitz Barchad26Lior Nesher27on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)Infectious Diseases Institute, Soroka University Medical Center, and the Faculty of Health Sciences, Ben-Gurion University of the NegevInfectious Diseases Institute, Soroka University Medical Center, and the Faculty of Health Sciences, Ben-Gurion University of the NegevDepartment of Clinical Microbiology and Infectious Diseases, Hadassah Medical CenterHematology Department, Soroka University Medical CenterClinical Research Center, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the NegevInternal Medicine D and Infectious Diseases Unit, Sheba Medical CenterInternal Medicine T, Sheba Medical CenterDepartment of Clinical Microbiology and Infectious Diseases, Hadassah Medical CenterDepartment of Clinical Microbiology and Infectious Diseases, Hadassah Medical CenterDepartment of Clinical Microbiology and Infectious Diseases, Hadassah Medical CenterDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care CampusDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care CampusDepartment of Infectious Diseases, AC Camargo Cancer CenterDepartment of Hematology and Cell Therapy, AC Camargo Cancer CenterInfectious Diseases Unit, Samson Assuta Ashdod University HospitalHematology Institute, Samson Assuta Ashdod University HospitalRappaport Faculty of Medicine, Technion-Israel Institute of TechnologyRappaport Faculty of Medicine, Technion-Israel Institute of TechnologyInfectious Diseases Unit, Rabin Medical Center, Beilinson HospitalDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer CenterDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer CenterInfectious Disease Unit, Internal Medicine Service, CIBERINFEC. Hospital Universitario La PazMeir Medical CentreInfectious Diseases Unit, Shamir (Assaf Harofeh) Medical CenterInfectious Diseases Unit, Shamir (Assaf Harofeh) Medical CenterDepartment of Infectious Diseases, VKV American Hospital, Koç University İşbank Center for Infectious Diseases (KUISCID)Infectious Disease Unit, Shaare Zedek Medical CenterInfectious Diseases Institute, Soroka University Medical Center, and the Faculty of Health Sciences, Ben-Gurion University of the NegevAbstract Introduction Despite the declining public health emergency status, COVID-19 still poses significant risks, especially for immunocompromised individuals. We aimed to evaluate the effectiveness of tixagevimab-cilgavimab (T-C) prophylaxis in preventing severe COVID-19 in patients with hematologic malignancies (HM) treated with anti-CD20 therapy during the early Omicron variant phase of the pandemic. Methods The European Society of Clinical Microbiology and Infectious Diseases Study Group for Respiratory Viruses (ESGREV) conducted a multicenter retrospective cohort study involving 15 centers from 5 countries. The study included 749 patients with HM treated with anti-CD20 between February 15 and June 30, 2022, comparing 215 who received T-C prophylaxis to 534 who did not. Results The study revealed a significant reduction in the risk of COVID-19 among patients who received T-C prophylaxis compared to those who did not (11.2% vs 23.4%, p < 0.001), with hazard ratio (HR) of 0.40 (95% CI 0.26–0.63), adjusted for age, sex, vaccination status, baseline HM malignancy and type of anti-CD-20. We also demonstrated a reduction for severe-critical diseases within all study populations, 1.4% vs 5.2%, p = 0.017, HR 0.26 (95% CI 0.08–0.84). Conclusion T-C prophylaxis effectively prevented COVID-19 and severe-critical COVID-19 in patients with HM treated with anti-CD20 monoclonal antibodies during the early Omicron variant phase of the pandemic. Even though T-C is ineffective against current variants, these findings highlight the importance of additional protective measures and the continued development of monoclonal antibodies to protect immunocompromised individuals to mitigate the impact of COVID-19 and other respiratory viral diseases.https://doi.org/10.1007/s40121-024-01089-9Anti-CD20Monoclonal antibodiesCOVID-19Hematologic malignanciesTixagevimab-cilgavimab |
| spellingShingle | Hovav Azuly Tali Shafat Daniel Grupel Tzvika Porges Ran Abuhasira Ana Belkin Ofir Deri Yonatan Oster Shadi Zahran Ehud Horwitz Netanel A. Horowitz Hazim Khatib Marjorie Vieira Batista Anita Cassoli Cortez Tal Brosh-Nissimov Yafit Segman Linor Ishay Regev Cohen Alaa Atamna Amy Spallone Roy F. Chemaly Juan Carlos Ramos Michal Chowers Evgeny Rogozin Noga Carmi Oren Şiran Keske Orit Wolfovitz Barchad Lior Nesher on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV) Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study Infectious Diseases and Therapy Anti-CD20 Monoclonal antibodies COVID-19 Hematologic malignancies Tixagevimab-cilgavimab |
| title | Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study |
| title_full | Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study |
| title_fullStr | Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study |
| title_full_unstemmed | Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study |
| title_short | Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study |
| title_sort | preventing severe covid 19 with tixagevimab cilgavimab in hematological patients treated with anti cd20 monoclonal antibodies an international multicenter study |
| topic | Anti-CD20 Monoclonal antibodies COVID-19 Hematologic malignancies Tixagevimab-cilgavimab |
| url | https://doi.org/10.1007/s40121-024-01089-9 |
| work_keys_str_mv | AT hovavazuly preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT talishafat preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT danielgrupel preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT tzvikaporges preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT ranabuhasira preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT anabelkin preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT ofirderi preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT yonatanoster preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT shadizahran preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT ehudhorwitz preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT netanelahorowitz preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT hazimkhatib preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT marjorievieirabatista preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT anitacassolicortez preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT talbroshnissimov preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT yafitsegman preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT linorishay preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT regevcohen preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT alaaatamna preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT amyspallone preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT royfchemaly preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT juancarlosramos preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT michalchowers preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT evgenyrogozin preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT nogacarmioren preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT sirankeske preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT oritwolfovitzbarchad preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT liornesher preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy AT onbehalfoftheeuropeansocietyofclinicalmicrobiologyandinfectiousdiseasesescmidstudygroupforrespiratoryvirusesesgrev preventingseverecovid19withtixagevimabcilgavimabinhematologicalpatientstreatedwithanticd20monoclonalantibodiesaninternationalmulticenterstudy |